Michael R. Hayden
Michael R. Hayden's purchase track record
How the stock did after each of Michael R. Hayden's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/24/2026 | ABCL | $570K | pending | pending | — |
| 8/12/2026 | ABCL | $481K | pending | pending | — |
| 7/30/2026 | IONS | $1.06M | pending | pending | — |
| 5/1/2025 | IONS | $478K | +35.5% | +133.9% | +21.7% |
| 12/23/2024 | IONS | $181K | -7.3% | +4.4% | +0.9% |
| 9/22/2023 | ABCL | $98K | +13.8% | -8.2% | +21.2% |
| 8/8/2023 | ABCL | $177K | -25.3% | -12.0% | +10.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Cathie Wood adds to Ionis position amid RNA sector interest. Cathie Wood has increased her holdings in Ionis Pharmaceuticals as part of a broader bet on two stocks. This move highlights continued investor interest in RNA therapeutics, a sector currently drawing attention for its innovation potential. While the stock is trading near its 52-week low, the average analyst target remains significantly higher than the current price.
Transaction History
| ABCL | ▲ Buy | Open Market | 53,613 | $570K | 8/24/2026 | View on chart |
| ABCL | ▲ Buy | Open Market | 46,387 | $481K | 8/12/2026 | View on chart |
| ABCL | ▼ Sell | Gift | 50,000 | $0 | 8/11/2026 | View on chart |
| IONS | ▲ Buy | Open Market | 5,000 | $258K | 7/31/2026 | View on chart |
| IONS | ▲ Buy | Open Market | 15,000 | $801K | 7/30/2026 | View on chart |
| IONS | ▲ Buy | Option Exercise | 4,079 | $0 | 7/15/2025 | View on chart |
| IONS | ▲ Buy | Open Market | 15,000 | $478K | 5/1/2025 | View on chart |
| IONS | ▲ Buy | Open Market | 2,500 | $90K | 12/23/2024 | View on chart |
| IONS | ▲ Buy | Open Market | 2,500 | $91K | 12/23/2024 | View on chart |
| ABCL | ▲ Buy | Open Market | 20,000 | $98K | 9/22/2023 | View on chart |
| ABCL | ▲ Buy | Open Market | 30,000 | $177K | 8/8/2023 | View on chart |
| IONS | ▲ Buy | Option Exercise | 5,333 | $0 | 7/17/2023 | View on chart |
| IONS | ▲ Buy | Option Exercise | 1,777 | $0 | 7/17/2023 | View on chart |
| IONS | ▲ Buy | Option Exercise | 1,777 | $0 | 10/17/2022 | View on chart |
| IONS | ▲ Buy | Option Exercise | 5,333 | $0 | 7/15/2022 | View on chart |
| IONS | ▲ Buy | Option Exercise | 1,777 | $0 | 7/15/2022 | View on chart |
| IONS | ▲ Buy | Option Exercise | 1,777 | $0 | 10/15/2021 | View on chart |
| ABCL | ▲ Buy | Option Exercise | 270,000 | $4.8M | 9/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ABCL: UBS Coverage, ABCL635 Data, and Phase 1/2 Results
UBS has begun coverage of AbCellera, setting a price target of $18. The company’s ABCL635 antibody is drawing attention after a recent analysis suggesting it may be undervalued by 27%. AbCellera will present Phase 1/2 data for ABCL635 at the TMS 2026 Annual Meeting, providing further insight into its clinical progress. These developments come as the broader biotech sector sees strong earnings from peers such as Nurix Therapeutics.
ABCL: UBS Coverage, ABCL635 Data, and Phase 1/2 Results. UBS has begun coverage of AbCellera, setting a price target of $18. The company’s ABCL635 antibody is drawing attention after a recent analysis suggesting it may be undervalued by 27%. AbCellera will present Phase 1/2 data for ABCL635 at the TMS 2026 Annual Meeting, providing further insight into its clinical progress. These developments come as the broader biotech sector sees strong earnings from peers such as Nurix Therapeutics.